Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2029-02-25
Target enrollment:
Participant gender:
Summary
The primary aim of the study is to establish the maximum-tolerated dose (MTD) of
225Ac-MTI-201 in participants with metastatic uveal melanoma. The secondary aims are to
describe the pharmacokinetics of 225Ac-MTI-201 and the toxic effects of 225Ac-MTI-201 in
participants with metastatic uveal melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Modulation Therapeutics, Inc.
Collaborator:
H. Lee Moffitt Cancer Center and Research Institute